TITLE

Lipodystrophy Syndrome and Self-Assessment of Well-Being and Physical Appearance in HIV-Positive Patients

AUTHOR(S)

Oette, Mark; Juretzko, Petra; Kroidl, Arne; Sagir, Abdurrahman; Wettstein, Matthias; Siegrist, Johannes; H�ussinger, Dieter

PUB. DATE

September 2002

SOURCE

AIDS Patient Care & STDs;Sep2002, Vol. 16 Issue 9, p413

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

The lipodystrophy syndrome (LDS) is a growing problem in human immunodeficiency virus (HIV)-positive patients treated with highly active antiretroviral therapy (HAART). It is characterized by alterations of body composition and metabolic abnormalities. The goal of the study was to investigate attitudes toward health condition, well-being, and individual appearance in relation to LDS. Outpatients between July and October 2000 in an HIV-specialized unit at the University Hospital of D�sseldorf, Germany, underwent clinical evaluation and received a standardized written questionnaire. Of 389 patients eligible for analysis, 313 patients returned completed questionnaires (response rate, 80.5%). LDS was observed in 37.7%; the predominant manifestation was lipoatrophy of the face (32.9%). Individuals with and without LDS did not differ significantly in their attitude to the quality of their health condition and the amount of disturbance of their well-being by HIV infection. Participants with LDS felt recognizable as HIV-positive by physical appearance in 30.1%, compared to 18.3% in patients without LDS (p = 0.027). This difference became more pronounced after adjustment for gender, age, stage of disease, CD4 cell count, and duration of HAART (odds ratio, 2.04, 95%-confidence interval [CI] 1.09-3.84). In conclusion, LDS does not seem to disturb the general attitude toward health condition and well-being. However, patients presenting with lipodystrophy are about twice as likely to feel recognizable as HIV-positive by their physical appearance. LDS may thus be perceived as a characteristic mark of being HIV-positive by affected persons. A stigmatizing effect and social disadvantages may be the consequences.

ACCESSION #

7411855

Tags: HIV-positive persons -- Research;  LIPIDS -- Metabolism -- Disorders

 

Related Articles

• Volunteers needed for study of HIV viral load test.  // AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p52 

  Reports that volunteers are needed from among HIV-infected persons for a study on HIV viral load. Who is carrying out study; How test will be done; How to obtain more information.

• Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeficiency Virus--Infected Patients. Ch � ne, Genevi � ve; Angelini, Emmanuelle; Cotte, Laurent; Lang, Jean-Marie; Morlat, Philippe; Rancinan, Corinne; May, Thierry; Journot, Val � rie; Raffi, Francois; Jarrousse, Bernard; Grappin, Mich � le; Lepeu, G � rard; Molina, Jean-Michel // Clinical Infectious Diseases;3/1/2002, Vol. 34 Issue 5, p649 

  Explores the role of nucleoside analogues in lipodystrophy (LD) syndrome and metabolic disorders in HIV-infected patients. Factors associated with LD syndrome; Prevalence of morphologic signs of LD and fasting metabolic parameters at month 30 of follow-up in patients; Hypotheses offered about...

• Gemfibrozil: Once-daily formulation may improve compliance.  // Geriatrics;Dec93, Vol. 48 Issue 12, p58 

  Reports on the findings of a study regarding the use of gemfibrozil for the control of dyslipidemia titled `Once-daily, extended release gemfibrozil in patients with dyslipidemia,' by AM Gotto Jr., WJ Breen, CN Corder et al.

• Hyperlipidaemia.  // GP: General Practitioner;11/11/2002, p75 

  Focuses on the disease hyperlipidaemia. Classification and screening of the disease; Symptoms of the disease; Assessing and treating hyperlipidaemia; Effect of Non-drug therapy.

• Lipid disorders are important causes of death and disability. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;03/25/98, Vol. 11 Issue 3, p28 

  Reports that the resulting vascular diseases of lipid disorders are the most important causes of death and disability in the United States.

• AACE releases consensus statement on detection of lipodystrophy.  // Endocrine Today;Mar2013, Vol. 11 Issue 3, p47 

  The article reports that a statement has been issued by the American Association of Clinical Endocrinologists outlining criteria for increasing the detection of lipodystrophy.

• lipodystrophy.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1348 

  A definition of the term "lipodystrophy," which refers to the disturbance of fat metabolism, is presented.

• remnant removal disease.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2000 

  A definition of the term "remnant removal disease" which refers to a lipid metabolism disorder marked by impaired uptake of lipoproteins by the liver is presented.

• Tenofovir failed to meet study endpoints in adolescents with HIM-1.  // Infectious Diseases in Children;Mar2012, Vol. 25 Issue 3, p14 

  The article discusses research on the safety of tenofovir disoproxil fumarate among HIV-1-positive adolescents, by Marinella Della Negra and colleagues, published in "Pediatrics Infectious Diseases Journal."

Read the Article